Three ETFs Poised to Profit From March’s Spike in Market Volatility

Why It Matters

The three ETFs highlighted combine two distinct defensive strategies: low‑cost, diversified exposure to India’s broad market and high‑growth exposure to biotech, a sector that has outperformed the S&P 500 by a wide margin in 2025. In a market environment where oil price spikes are inflating inflation expectations and prompting a hawkish Fed stance, traditional safe‑haven assets like gold are losing appeal. Investors need alternatives that can both preserve capital and capture upside. The Nifty100 fund offers a cost‑effective entry into a large‑cap basket with a modest valuation, while the biotech ETFs tap a sector whose earnings growth is driven by demographic trends and a wave of FDA approvals, making them less correlated with energy‑price shocks. If the Iran conflict escalates further, oil‑related volatility could deepen, pressuring equity markets across the board. In such a scenario, the defensive tilt of the Nifty100 and the growth tilt of biotech could provide a balanced hedge, allowing portfolios to weather short‑term turbulence while staying positioned for longer‑term upside. The performance of these ETFs over the coming weeks will be a bellwether for how investors navigate geopolitical risk and sector rotation in 2026.

Key Takeaways

• Bandhan Nifty100 Index Fund: 0.10 % expense ratio, 0.20 % tracking difference, 12.6 % five‑year rolling return.
• Virtus LifeSci Biotech Clinical Trials ETF (BBC): 63.7 % YTD return, focused on clinical‑stage biotech firms.
• iShares Biotech ETF (IBB): 28.0 % 2025 return, broad exposure to biotech leaders.
• Iran‑related oil shock lifted Brent to $112/barrel, pushing the 10‑year Treasury yield to 4.37 %.
• Gold fell 11 % in a week, with gold ETFs shedding over 60 tonnes in three weeks.

Pulse Analysis

The current market environment is defined by a classic risk‑on/risk‑off swing. The Iran‑Israel‑U.S. confrontation has re‑priced oil risk, spiking commodity prices and forcing the Fed to reconsider its dovish outlook. Historically, such macro shocks have driven investors toward defensive, low‑beta assets or sectors with earnings that are insulated from energy price swings. The Nifty100 fund fits the former category: it offers a diversified, low‑cost exposure to India’s large‑cap universe at a valuation that still carries a discount to its historical average. Its modest expense ratio makes it an attractive vehicle for retail investors who are wary of high‑frequency trading costs in volatile markets.

Conversely, the biotech sector is a rare case of a growth theme that thrives amid uncertainty. The surge in FDA approvals and the massive $8.5 billion flow into longevity science signal a structural shift: biotech is moving from a speculative niche to a core component of future healthcare spending. The BBC’s 63.7 % return underscores how clinical‑stage companies can deliver outsized gains when regulatory pipelines clear. However, the sector’s volatility is higher than that of broad equity indices, meaning investors must balance the upside against potential drawdowns if the Fed’s hawkish stance dampens risk appetite.

Putting the two together creates a tactical blend: the Nifty100 fund provides a stable, low‑cost foundation, while the biotech ETFs add a high‑growth, low‑correlation overlay. As the war in the Persian Gulf drags on, oil‑driven inflation could keep real yields elevated, eroding the appeal of traditional safe‑havens like gold. Investors who can tolerate the biotech’s beta may find that the sector’s earnings momentum outpaces the broader market’s slowdown, delivering a net positive return even as equity indices wobble. The key risk remains the duration of the geopolitical conflict; a rapid de‑escalation could see oil prices retreat, easing inflation pressures and potentially restoring a more balanced risk‑on environment. Until then, the three‑ETF playbook offers a pragmatic hedge against the twin threats of commodity‑driven inflation and equity market volatility.